Question to the Department for Environment, Food and Rural Affairs:

To ask His Majesty's Government what consideration they have given to restricting tick and flea treatments for pets containing fipronil or imidacloprid to prescription only, in the light of evidence of their human and environmental toxicity and their detrimental effects on aquatic life.

Parasiticides, such as those containing fipronil and imidacloprid, play an essential role in protecting both animal and human health against fleas and ticks and their associated vector-borne diseases, which can lead to parasitic disease in pets and present zoonotic risks to humans, as well as causing distress and discomfort. The concerns regarding the potential contribution of flea and tick treatments to the levels of imidacloprid currently being detected in UK surface waters are recognised. The Veterinary Medicine Directorate (VMD) is currently gathering evidence on this issue and has initiated the formation of a cross-governmental Pharmaceuticals in the Environment (PiE) Group.

The PiE Group has set out a roadmap of activities to address levels of fipronil and imidacloprid in UK waterways. The immediate priority is to collaborate with key stakeholders to enhance and promote consistent messaging to users on the appropriate use of topical parasiticides for cats and dogs, aiming to reduce potential environmental impacts. Beyond this, actions will focus on developing our evidence base through research and monitoring. The group will use this evidence to improve understanding of the issue and inform future policy activities in the longer term.

At this stage, there are no plans to restrict flea and tick treatments to prescription only. Any future regulatory decisions will be based on robust scientific evidence to ensure both environmental protection and continued access to essential veterinary medicines.